Isofol attends the French-Swedish Life Science Day 2017

Isofol attends the French-Swedish Life Science Day 2017
December 14, 2017 Admin Isofol

December 14, 2017

Isofol attends the French-Swedish Life Science Day 2017

The French-Swedish Life Science Day 2017 conference gathers highly innovative biotech companies from Sweden, French and Swedish life science investors as well as executives from pharmaceutical companies. The goal of the conference is to create an arena for French and Swedish players to establish new contacts and to identify business opportunities.

The conference take place at the Swedish Embassy in Paris, France, during the 14th of December.

For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
E­mail: anders.rabbe@isofolmedical.com
Phone: +46 (0)707 646 500

About Modufolin®
Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study.

About Isofol Medical AB
Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

www.isofol.se